OTCMKTS:OXBDF Oxford BioMedica (OXBDF) Stock Price, News & Analysis $4.28 0.00 (0.00%) As of 06/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Oxford BioMedica Stock (OTCMKTS:OXBDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oxford BioMedica alerts:Sign Up Key Stats Today's Range$4.28▼$4.2850-Day Range$3.93▼$4.6652-Week Range$3.15▼$5.68VolumeN/AAverage Volume29 shsMarket Capitalization$453.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More… Receive OXBDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford BioMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXBDF Stock News HeadlinesOxford BioMedica completes purchase of last 10% stake in US subsidiaryJune 23, 2025 | lse.co.ukOxford BioMedica touts strong first-half momentum ahead of meetingJune 11, 2025 | lse.co.ukI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)Oxford Biomedica Full Year 2024 Earnings: EPS Beats ExpectationsMay 1, 2025 | finance.yahoo.comOxford BioMedica (OXBDF) Receives a Buy from RBC CapitalApril 15, 2025 | theglobeandmail.comWhen Will Oxford Biomedica plc (LON:OXB) Turn A Profit?April 10, 2025 | uk.finance.yahoo.comOxford Biomedica sees FY25 revenue GBP 160M-GBP 170MApril 9, 2025 | msn.comOxford Biomedica prepares statements on ‘going concern basis’April 9, 2025 | msn.comSee More Headlines OXBDF Stock Analysis - Frequently Asked Questions How have OXBDF shares performed this year? Oxford BioMedica's stock was trading at $5.3950 at the beginning of the year. Since then, OXBDF stock has decreased by 20.7% and is now trading at $4.2763. View the best growth stocks for 2025 here. How do I buy shares of Oxford BioMedica? Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:OXBDF Previous SymbolNASDAQ:OXBDF CIKN/A Webwww.oxfordbiomedica.co.uk Phone44-18-6578-3000FaxN/AEmployees891Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$111.34 million Price / Sales4.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book4.23Miscellaneous Outstanding Shares105,960,000Free FloatN/AMarket Cap$453.12 million OptionableNot Optionable Beta1.14 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:OXBDF) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford BioMedica Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford BioMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.